• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Autoimmune Diseases

China US deals flags MA
Biotech

Vor pays RemeGen $10M for long-acting autoimmune drug successor

Vor Bio is paying RemeGen $10 million upfront to add a long-acting autoimmune drug candidate to its BAFF/APRIL pipeline.
Nick Paul Taylor Nov 12, 2026 10:16am
pipeline pipes RD research

Kyverna abandons next-gen CAR-T once touted as miv-cel follow-up

Nov 12, 2026 10:06am
AbCellera high throughput lab robot

AbCellera becomes latest biotech to abandon OX40 drug

Nov 10, 2026 5:06am
Pipette dripping water droplet with money symbol on it into test tube

T-Therapeutics raises $133M series B with Big Pharma backers

Nov 5, 2026 4:00am
handshake deal shake hand arrows ok yes

Celltrion picks up another Kaigene antibody for up to $580.5M

Oct 22, 2026 10:22am
Pfizer ADA

Pfizer makes 'business decision' to end trial of autoimmune drug

Oct 20, 2026 6:59am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings